Share class: Harmony Biosciences Holdings, Inc.

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A157,031,29738,573,136 ( 67.64 %) 0 67.64 %

Major shareholders: Harmony Biosciences Holdings, Inc.

NameEquities%Valuation
Valor Management LLC
11.6 %
6,618,033 11.6 % 257 M $
BlackRock Advisors LLC
11.48 %
6,547,746 11.48 % 254 M $
Marshman Fund Trust Ii
10.61 %
6,051,120 10.61 % 235 M $
Fidelity Management & Research Co. LLC
9.168 %
5,228,720 9.168 % 203 M $
The Vanguard Group, Inc.
8.3 %
4,733,609 8.3 % 184 M $
Vanguard Fiduciary Trust Co.
8.3 %
4,733,609 8.3 % 184 M $
Vivo Capital LLC
4.57 %
2,606,247 4.57 % 101 M $
Pacer Advisors, Inc.
3.998 %
2,279,918 3.998 % 88 M $
HBM Partners AG (Investment Management)
3.766 %
2,147,943 3.766 % 83 M $
State Street Corp.
2.175 %
1,240,598 2.175 % 48 M $
░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░

Breakdown by shareholder type

Institutional89.23%
Other17.5%
State Street Corp.2.18%
Individuals0.51%
Schweizerische Nationalbank0.14%
Governments0.11%
Corebridge Financial, Inc.0.04%
StoneX Group, Inc.0.03%
Manulife Financial Corp.0.03%
Oakworth Capital, Inc.0.02%
Hancock Whitney Corp.0.02%

Based on 1000 largest holdings

Geographical origin of shareholders

United States 99.95%
Switzerland 3.93%
Australia 1.77%
United Kingdom 1.77%
Ireland 0.65%
Individuals 0.51%
Canada 0.37%
Sweden 0.33%
Norway 0.26%
Denmark 0.07%
Israel 0.06%
Hong Kong 0.05%
Austria 0.02%
China 0.02%
Cayman Islands 0.02%
Germany 0.01%
Luxembourg 0.01%
Finland 0.01%

Based on 1000 largest holdings

Logo Harmony Biosciences Holdings, Inc.
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company. It is focused on developing and commercializing therapies for patients living with rare neurological diseases as well as patients living with other neurological diseases who have unmet medical needs. Its product, WAKIX (pitolisant), is a first-in-class molecule with a novel mechanism of action designed to enhance histamine signaling in the brain by binding to H3 receptors. Its WAKIX is developed for the treatment of excessive daytime sleepiness (EDS) in adult patients with narcolepsy and treatment of cataplexy in adult patients with narcolepsy. It also provides HBS-102, an investigational compound, which is a melanin-concentrating hormone receptor 1 (MCHR1) antagonist that targets MCH neurons in the brain. It also develops ZYN002, a pharmaceutically manufactured synthetic cannabidiol. It is also focused on the rare epilepsy franchise in its expanding late-stage pipeline of CNS assets: EPX-100 and EPX-200.
Employees
246
More about the company